SCHEMBL25204580

SCHEMBL25204580

COC(=O)c1ccc(N2CC3(CC(=O)C3)C2)cc1Oc1cnc2[nH]ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 17/20 0.47
BCL2L1 Q07817 3/20 0.46
BCL2A1 Q16548 3/20 0.41
BID P55957 2/20 0.40
MCL1 Q07820 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23323413 0.91 BCL2 (0.55) BCL2BCL2L1BCL2A1
SCHEMBL30415477 0.91 BCL2 (0.55) BCL2BCL2L1BCL2A1
SCHEMBL23943781 0.83 BCL2 (0.36) BCL2BCL2L1
SCHEMBL1702063 0.83 BCL2 (0.50) BCL2BCL2L1BCL2A1BIDMCL1
SCHEMBL19867786 0.83 BCL2 (0.50) BCL2BCL2L1BCL2A1BIDMCL1
SCHEMBL24775466 0.82 BCL2 (0.55) BCL2BCL2L1BCL2A1BIDMCL1
SCHEMBL31321339 0.82 BCL2 (0.55) BCL2BCL2L1BCL2A1BIDMCL1
SCHEMBL25640578 0.82 BCL2 (0.47) BCL2BCL2L1
SCHEMBL30313985 0.82 BCL2 (0.47) BCL2BCL2L1BCL2A1BIDMCL1
SCHEMBL28839728 0.82 BCL2 (0.51) BCL2BCL2L1BCL2A1BIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270210-A1 BCL-2 Inhibitor BEIGENE, LTD. (KY) 2025-08-28 US disclosed
US-12286430-B2 Bcl-2 inhibitor BEIGENE, LTD. (KY) 2025-04-29 US disclosed
US-20240376097-A1 BCL-2 Inhibitor BEIGENE LTD. (KY) 2024-11-14 US disclosed
US-20230159522-A1 BCL-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270210-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 BCL2 1/4885BCL2L1 3/4885BCL2A1 2/4885
US-20230159522-A1 BCL-2 INHIBITOR BCL2, BCL2A1, BCL2L1 BCL2 1/4885BCL2L1 3/4885BCL2A1 2/4885
US-20240376097-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 BCL2 1/4885BCL2L1 3/4885BCL2A1 2/4885
US-12286430-B2 Bcl-2 inhibitor BCL2, BCL2A1, BCL2L1 BCL2 1/4885BCL2L1 3/4885BCL2A1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.